NYSE:MRK
Merck & Company (MRK)
Financials 
Technical Analysis 
Jun 2, 2026, 12:00 amThis summary was created by AI, based on 21 opinions in the last 12 months.
Merck & Company (MRK) is facing challenges with its key cancer drug, Keytruda, approaching patent expiry in 2028, which currently contributes significantly to its revenue. However, experts note that the company's R&D pipeline remains robust, with many promising drugs in various stages of development that may offset potential revenue losses from Keytruda. Despite a mixed outlook on the pharmaceutical sector due to pricing pressures and competition, many analysts express confidence in Merck’s strategic acquisitions and investments in new drugs. The stock is perceived as a well-managed entity with a solid dividend yield and a comparatively strong balance sheet, yet concerns linger regarding its overall valuation relative to its historical growth rates. Overall, while the company is navigating through market headwinds, there remains optimism about its long-term growth trajectory due to innovations and strategic positioning in the healthcare sector.
Today's downward move isn't all that outsized. There's been more clarity on US drug pricing. Seeing a bit of market exhaustion, as US pharma is trading at huge premiums relative to their own history.
Rerating from pricing clarity has already been baked in. R&D pipeline in the sector is a mixed bag, doesn't trust it.
He bought it for their strong drug pipeline and is happy to stay here.
Gordon ReidOne of her holdings in the space. This higher-quality name has both growth and less execution risk.
Brianne Gardner
;fill-opacity:1;'/%3e%3cpath%20d='M31%2018.6001V30H8V18.6001L14.1334%2022.4334L19.4999%2014L24.8669%2022.4334L31%2018.6001Z'%20fill='%23EE5432'%20style='fill:%23EE5432;fill:color(display-p3%200.9340%200.3310%200.1956);fill-opacity:1;'/%3e%3c/svg%3e){kind=small}
Premium content
Pharmas are coming back. Political policy is improving. Keytruda makes up a lot of revenues but faces a patent cliff in 2028. But MRK has invested a lot in new drugs and been buying companies strategically.
(Analysts’ price target is $123.89)
Julien Nono-WomdimPremium content
They have a good pipeline that will help offset the loss of their major Keytruda drug when it goes off-patent. MRK is good at buying and tucking in companies. Their 2025 chart wasn't that great until the end of the year when the sector caught a bid.
Gordon Reid
Premium content
Premium content'%20fill='%23ffffff'%3e%3cg%20id='Pager'%20transform='translate(423.000000,%201755.000000)'%3e%3cpath%20d='M243.295367,17.286474%20C243.68919,16.9045087%20244.327703,16.9045087%20244.721525,17.286474%20L249,21.4361302%20L253.278475,17.286474%20C253.672297,16.9045087%20254.31081,16.9045087%20254.704633,17.286474%20C255.098456,17.6684393%20255.098456,18.2877274%20254.704633,18.6696927%20L249.35654,23.856763%20C249.159628,24.0477457%20248.840372,24.0477457%20248.64346,23.856763%20L243.295367,18.6696927%20C242.901544,18.2877274%20242.901544,17.6684393%20243.295367,17.286474%20Z'%20id='Path'%20transform='translate(249.000000,%2020.500000)%20rotate(-90.000000)%20translate(-249.000000,%20-20.500000)%20'%3e%3c/path%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
Merck & Company (MRK) Frequently Asked Questions
What is Merck & Company stock symbol?
Merck & Company is a American stock, trading under the symbol MRK (previously MRK-N on Stockchase) on the New York Stock Exchange (MRK). It is usually referred to as NYSE:MRK or MRK
Is Merck & Company a buy or a sell?
In the last year, 19 stock analysts published opinions about MRK (previously MRK-N on Stockchase). 13 analysts recommended to BUY the stock. 3 analysts recommended to SELL the stock. The latest stock analyst recommendation is PAST TOP PICK. Read the latest stock experts' ratings for Merck & Company.
Is Merck & Company a good investment or a top pick?
Merck & Company was recommended as a Top Pick by The Panic-Proof Portfolio (Stockchase Research) on 2025-11-13. Read the latest stock experts ratings for Merck & Company.
Why is Merck & Company stock dropping?
Earnings reports or recent company news can cause the stock price to drop. Read stock experts' recommendations for help on deciding if you should buy, sell or hold the stock.
Is Merck & Company worth watching?
19 stock analysts on Stockchase covered Merck & Company in the last year. It is a trending stock that is worth watching.
What is Merck & Company stock price?
On 2026-06-03, Merck & Company (MRK) stock closed at a price of $115.66.
Many drugs in the pipeline, and this compensates for older drugs going off patent. For example, it's blockbuster Keytruda is going off. You want companies that deliver double-digit revenue growth on offerings.